PMC:7105881 / 761-1431 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"49","span":{"begin":32,"end":38},"obj":"Species"},{"id":"50","span":{"begin":82,"end":90},"obj":"Species"},{"id":"51","span":{"begin":95,"end":103},"obj":"Species"},{"id":"52","span":{"begin":227,"end":232},"obj":"Species"},{"id":"53","span":{"begin":285,"end":294},"obj":"Species"},{"id":"54","span":{"begin":354,"end":361},"obj":"Species"},{"id":"55","span":{"begin":460,"end":468},"obj":"Species"},{"id":"56","span":{"begin":473,"end":481},"obj":"Species"},{"id":"57","span":{"begin":525,"end":531},"obj":"Species"},{"id":"58","span":{"begin":622,"end":627},"obj":"Species"},{"id":"59","span":{"begin":628,"end":632},"obj":"Species"},{"id":"71","span":{"begin":108,"end":116},"obj":"Disease"},{"id":"72","span":{"begin":233,"end":243},"obj":"Disease"},{"id":"73","span":{"begin":446,"end":456},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:694009"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:1335626"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:2697049"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:2697049"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:694009"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:1335626"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:9606"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:11118"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D015047"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:D007239"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":601,"end":609},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":82,"end":90},"obj":"Disease"},{"id":"T8","span":{"begin":233,"end":243},"obj":"Disease"},{"id":"T9","span":{"begin":446,"end":456},"obj":"Disease"},{"id":"T10","span":{"begin":460,"end":468},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":117,"end":124},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T8","span":{"begin":132,"end":136},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T9","span":{"begin":227,"end":232},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T10","span":{"begin":396,"end":397},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T11","span":{"begin":496,"end":499},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T12","span":{"begin":525,"end":531},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T13","span":{"begin":622,"end":627},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":601,"end":609},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":77,"end":244},"obj":"Sentence"},{"id":"T8","span":{"begin":245,"end":386},"obj":"Sentence"},{"id":"T9","span":{"begin":387,"end":532},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T20","span":{"begin":32,"end":38},"obj":"NCBITaxon:9606"},{"id":"T21","span":{"begin":82,"end":90},"obj":"SP_10"},{"id":"T22","span":{"begin":95,"end":103},"obj":"SP_9"},{"id":"T23","span":{"begin":117,"end":124},"obj":"NCBITaxon:10239"},{"id":"T24","span":{"begin":132,"end":136},"obj":"SP_2;NCBITaxon:6960"},{"id":"T25","span":{"begin":227,"end":232},"obj":"SP_6;NCBITaxon:9606"},{"id":"T26","span":{"begin":285,"end":294},"obj":"SP_7"},{"id":"T27","span":{"begin":460,"end":468},"obj":"SP_10"},{"id":"T28","span":{"begin":473,"end":481},"obj":"SP_9"},{"id":"T29","span":{"begin":525,"end":531},"obj":"NCBITaxon:9606"},{"id":"T30","span":{"begin":622,"end":627},"obj":"SP_6;NCBITaxon:9606"},{"id":"T67198","span":{"begin":32,"end":38},"obj":"NCBITaxon:9606"},{"id":"T95796","span":{"begin":82,"end":90},"obj":"SP_10"},{"id":"T29232","span":{"begin":95,"end":103},"obj":"SP_9"},{"id":"T37092","span":{"begin":117,"end":124},"obj":"NCBITaxon:10239"},{"id":"T43831","span":{"begin":132,"end":136},"obj":"SP_2;NCBITaxon:6960"},{"id":"T95839","span":{"begin":227,"end":232},"obj":"SP_6;NCBITaxon:9606"},{"id":"T58242","span":{"begin":285,"end":294},"obj":"SP_7"},{"id":"T89984","span":{"begin":460,"end":468},"obj":"SP_10"},{"id":"T56264","span":{"begin":473,"end":481},"obj":"SP_9"},{"id":"T11552","span":{"begin":525,"end":531},"obj":"NCBITaxon:9606"},{"id":"T28582","span":{"begin":622,"end":627},"obj":"SP_6;NCBITaxon:9606"}],"text":"ently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types"}